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ABSTRACT
Hypomethylation of LINE-1 repeats in cancer has been proposed as the main mechanism behind their
activation; this assumption, however, was based on ﬁndings from early studies that were biased toward
young and transpositionally active elements. Here, we investigate the relationship between methylation of
2 intergenic, transpositionally inactive LINE-1 elements and expression of the LINE-1 chimeric transcript
(LCT) 13 and LCT14 driven by their antisense promoters (L1-ASP). Our data from DNA modiﬁcation,
expression, and 50RACE analyses suggest that colorectal cancer methylation in the regions analyzed is not
always associated with LCT repression. Consistent with this, in HCT116 colorectal cancer cells lacking DNA
methyltransferases DNMT1 or DNMT3B, LCT13 expression decreases, while cells lacking both DNMTs or
treated with the DNMT inhibitor 5-azacytidine (5-aza) show no change in LCT13 expression. Interestingly,
levels of the H4K20me3 histone modiﬁcation are inversely associated with LCT13 and LCT14 expression.
Moreover, at these LINE-1s, H4K20me3 levels rather than DNA methylation seem to be good predictor of
their sensitivity to 5-aza treatment. Therefore, by studying individual LINE-1 promoters we have shown
that in some cases these promoters can be active without losing methylation; in addition, we provide
evidence that other factors (e.g., H4K20me3 levels) play prominent roles in their regulation.
Abbreviations: LINE-1, long interspersed element 1; LCT, LINE-1 chimeric transcript; L1-ASP, LINE-1 antisense pro-
moter; 5-aza, 5-azacytidine; hMeDIP, hydroxymethylated DNA immunoprecipitation; 5hmC, 5-hydroxymethylcyto-
sine; ChIP, chromatin immunoprecipitation
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Introduction
Long interspersed element 1 (LINE-1) regions are repetitive
DNA sequences that comprise about 17% of the human
genome, equivalent to approximately 8 times the protein cod-
ing portion of the genome.1 LINE-1s are autonomous mobile
elements that carry their own promoters and the information
to copy and paste themselves to different locations in the
genome, a phenomenon known as retrotransposition.2 Of the
about 516,000 LINE-1s present in the human genome, just
around 7000 have retained potentially intact promoters; of
these, nearly 5000 are full-length but only up to 20 so called
‘hot-L1s’ have been shown to be able to retrotranspose.3–5
It is now becoming more widely accepted that LINE-1s can
also contribute to tumor in ways that are not related to their
mobilization.6–8 Some of these effects (e.g., the ability of LINE-
1 promoters to act as alternative promoters for protein coding
genes9) are due to transcription from the LINE-1 promoters
and therefore can be exerted by all elements carrying intact
promoters and not restricted to the few hot-L1s. LINE-1s
contain an internal bidirectional promoter within their 50
untranslated region (L1–50UTR): a sense promoter (L1-SP)
responsible for transcription of the element itself, and an anti-
sense promoter (L1-ASP) driving transcription away from the
element.10,11 L1-ASP activity has been mapped between posi-
tions 400 and 600 of the L1–50UTR using transgenic constructs
carrying retrotransposition competent LINE-1s.12 L1-ASP
activity in this region was further conﬁrmed in human embry-
onic stem and carcinoma cells.13 More recently, this activity
has been shown to drive expression of the ORF0 protein with
transposition enhancing properties and coded by about 781
LINE-1 loci in the human genome.14 Transcription initiation
from L1-ASP in cancer has also been found between position
160 and 200 of the L1–50UTR, in particular for intergenic, ret-
rotransposition deﬁcient LINE-1s.10,15
It has been proposed that DNA methylation has evolved to
prevent potentially damaging effects by silencing endogenous
retrotransposons.16,17 Indeed, in somatic cells these elements
are silenced and heavily methylated.18-20 By contrast,
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hypomethylation of LINE-1s is a common feature of cancer
cells,21 which has been associated with LINE-1s activation and
consequent further promotion of genome instability and cancer
progression.22–24 In general, LINE-1 methylation levels
decrease as the severity index of the cancer increases.25–27
LINE-1 activity and new somatic LINE-1 insertions have been
described in several cancers of epithelial cell origin and happen
at particularly high frequencies in colorectal tumors.28 These
observations have led to the notion that hypomethylation is the
primary cause of activation of LINE-1 promoters in cancer.
However, the evidence supporting this order of events is not
conclusive.
Given their abundance and propensity to be methylated,
LINE-1 methylation levels have been often used as a surrogate
measure for global DNA methylation.29,30 However, until
recently, the majority of LINE-1 methylation studies have
looked at global levels using methods that favor detection of
young and transpositionally active elements.31 These global
studies lack resolution and assume one general regulatory net-
work or machinery for all LINE-1 elements within the genome
irrespective of cellular context. This is an unlikely scenario
since LINE-1 elements can be found in a variety of loci and
carry individual or familial SNPs. In agreement with this, there
are numerous individual examples of LINE-1 elements that do
not conform to the global methylation trends. Smith et al.32
identiﬁed a subset of LINE-1 elements that were hypomethy-
lated in oocytes despite the majority of transcription elements
maintaining a heavy methylation status. In cancer, Phokaew
et al.33 showed that some LINE-1s are not affected by global
hypomethylation. Similarly, generalized activation of LINE
expression was not observed in mouse hypomethylation
models.34,35
These observations highlight the importance of studying
individual LINE-1 elements to advance our understanding of
their regulatory mechanism. Despite this, locus-speciﬁc LINE-1
studies are sparse and they are mainly focused on elements
located within the body of annotated genes (intragenic LINE-
1s) and their immediate effect on their host gene.36,37 We previ-
ously identiﬁed transcripts initiating at L1-ASP, which we
referred to as LINE-1 chimeric transcripts or LCTs because
they contain within the same molecule both LINE-1 and
unique sequences.15 Of particular interest, 2 LCTs (LCT13 and
LCT14) were found to initiate at the antisense promoter (L1-
ASP) of transpositionally inactive L1PA2 elements located at
Figure 1. Relationship between methylation and expression of LCT13 L1ASP in CRC. (A) Top: Schematic diagram of the LCT13 genomic locus on human chromosome 7
(chr7:93,204,042–93,540,485; center) with indicated the positions of the CALCR, TFPI-2, and GNGT1 genes and of the 2 intact intergenic LINE1s (L1) present in this region.
Middle: enlargement of the LINE-1 (L1PA2: chr7:93,213,393–93,221,079, with an SVA_D spanning the interval 93,214,544–93,216,214) from which LCT13 originates with
the regions (black bars) tested by bisulﬁte or hMeDIP and ChIP. Bottom: enlargement of the LCT13 spliced transcript with indicated its exon structure [LINE-1 50UTR frag-
ment in light gray (chr7:93,220,882–93,221,083) and, in dark gray, the 2 GNGT1 exons (93,536,051–93,536,154 and 93,540,102–93,540,235), part of the LCT13 transcript].
Also indicated are the positions of the Taqman assay used for LCT13 expression studies located at the splice junction (black bar) and of the primers used for 50RACE
(arrows). All coordinates are from hg19 annotations; scale is in kilobase pairs (kb). (B) Bar charts showing the expression of LCT13 measured by real time RT-PCR and
expressed relatively to the geometric mean of 3 reference genes in matched normal (dark gray, N) and tumor (light gray, T) tissues from 6 colorectal cancer patients (left
panel) and 6 cell lines (right panel). NC: normal colon, commercially sourced total RNA from 7 healthy donors pooled together. (C) Bar charts of the methylation levels
measured by bisulﬁte sequencing in the tissues of the 6 patients and cell lines presented in B.
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intergenic regions (between genes) on human chromosomes 7
and 5 respectively.15,38 We further demonstrated that in up to
50% of colorectal cancers lacking expression of the tumor sup-
pressor gene TFPI-2, this silencing is associated with the pres-
ence of the overlapping anti-sense LCT13 transcript, suggesting
that its expression may have a functional consequence in can-
cer.38 In an ES cell line model an antisense transcript can
silence TFPI-2 expression before de novo methylation of its
promoter in differentiated cells.38 Our initial observations in
MCF10A non-neoplastic breast cells suggested that in breast
hypomethylation is involved in activation of the promoters of
these intergenic L1PA2s15; however, it remains unclear whether
loss of DNA methylation is always necessary to activate them
in cancer. In this study, we have investigated at a locus-speciﬁc
level if loss of DNA methylation within the L1–50UTR of the
LINE-1s driving LCT13 and LCT14 is always associated with
their expression, and we have also compared the presence of
histone marks associated with active and inactive chromatin
states to transcriptional activity and DNA methylation levels at
these sites.
Results
Relationship between activity and methylation of LCT13 in
cancer
We previously showed that aberrant activation of LINE-1 anti-
sense promoters in cancer can occur at older and transposition
deﬁcient elements,15 such as the L1-ASP of the L1PA2 that
drives expression of LCT13 (Fig. 1A).38 To determine whether
this activity was associated with a decrease in methylation, we
compared expression of LCT13 to its methylation in matched
normal and tumor tissues from 6 colorectal cancer (CRC)
donors (26, 29, 30, 33, 65 and 104). In addition, 3 microsatellite
instable (MSI: HCA-7, HCT116, RKO) and 3 microsatellite sta-
ble (MSS: CaCo-2; SW480 and SW620) CRC cell lines were
tested as higher levels of methylation at LINE-1s have been
reported in MSI relatively to MSS lines.36 The patients used for
this study were chosen based on their LCT13 expression proﬁle:
29 expresses LCT13 in the normal mucosa (N) but not in the
tumor (T); 26 and 33 express LCT13 in N and at increased lev-
els in T; 30, 65 and 104 expressed LCT13 only in T, the most
commonly found pattern (Fig. 1B, left panel).38 Using the same
quantitative RT-PCR approach in the CRC cell lines, we found
that HCT116 express the highest levels of LCT13, followed by
CaCo-2, HCA-7 and SW620; by contrast, LCT13 expression in
RKO and SW480 is not detectable (Fig. 1B, right panel). We
then studied, by PCR on bisulﬁte treated DNA, the methylation
of a region of the L1–50UTR of the LINE-1 driving expression
of LCT13 (bisulﬁte, Fig. 1A middle diagram) in the same
patient tissues and cell lines used for the expression analysis.
With the exception of patients 33 and 30, where there was a
decrease in methylation in the tumor tissue (T) samples,
LCT13 is surprisingly highly methylated (>80%) in both nor-
mal (N) and T samples from all other patients studied (Fig. 1C,
left panel; Fig. S2A). Moreover, this L1–50UTR region is also
highly methylated in the 6 CRC cell lines, regardless of their
expression proﬁle (Fig. 1C, right panel; Fig. S2A). Interestingly,
in breast cancer (BC) cell lines the expected relationship
between levels of methylation and expression of LCT13 was
observed, with increasing amounts of expression corresponding
to decreasing levels of methylation. However, while T47D are
unmethylated, MCF7 and HCC1954 retain >55% methylation
(Fig. S2B and C). These ﬁndings suggest that, at least in CRC,
loss of methylation may not be necessary for LINE-1 promoter
activation, or, alternatively, that LCT13 expression in methyl-
ated tissues and cell lines may initiate at a different promoter.
LCT13 transcription is driven by L1-ASP
To address whether LCT13 transcription was driven by L1-ASP
in the expressing cell lines, we performed 50RACE anchored in
the second exon of the LCT13 transcript (Fig. 1A, bottom dia-
gram). We ﬁrst optimized conditions in MCF7 cells as we have
previously been able to identify LCT13 transcription start sites
(TSS) in these cells.15 The use of a variety of conditions
highlighted the presence of weak and strong TSSs all within
L1–50UTR (Fig. S3). Using conditions optimal for the major
TSS, we obtained 50RACE products for all cell lines analyzed
with the exception of RKO and SW480, consistent with the
lack of expression of LCT13 in these 2 lines. In all positive cell
lines LCT13 transcripts have a major transcription start site
(TSS) within L1–50UTR, conﬁrming that L1-ASP drives LCT13
expression in these cells (Fig. 2A). We next analyzed each TSS
in the context of the average methylation of L1–50UTR within
the respective cell line. This revealed that the major TSS was sit-
uated within the methylated region of L1–50UTR in HCT116
and MCF7, while in CaCo-2 and SW620 it lies just outside the
CpG rich region studied by bisulﬁte sequencing (Fig. 2B). In
addition, HCC1954 has 2 TSSs that, judging by the relative
amounts of 50RACE products, seem to be used at similar levels:
one TSS is in a similar location to that of MCF7 cells; the other
is close to the TSS identiﬁed in HCT116 and T47D cells and sit-
uated within a methylated region (Fig. 2B). This data suggest
that, similar to many other RNA polymerase II promoters, the
L1-ASP driving LCT13 has scattered TSSs and that in some
cases (e.g., HCT116) transcription initiation may occur despite
the presence of DNA methylation; alternatively, the detection
of methylation by bisulﬁte may indicate the presence of
hydroxymethylated cytosine.
The co-occurrence of DNA methylation and expression of
LCT13 and LCT14 is not due to increased levels of
hydroxymethylcytosine
To address whether the observations made at LCT13 were
unique to this particular locus, we analyzed the relationship
between DNA methylation and expression of another inter-
genic LCT (LCT14), which we previously identiﬁed as initiating
from the L1-ASP of an intergenic L1PA2 on chromosome 5
(Fig. 3A).15 We selected matched normal (N) and tumor (T)
tissues from 4 CRC donors, 2 that did not show any LCT14
expression in N or T (148 and 218), one that expressed LCT14
in both N and T (153) and one that did not express LCT14 in
N but did in T (205) (Fig. 3B, left panel). DNA methylation lev-
els were above 80% in all tissue samples, including those
expressing LCT14 (Fig. 3C left panel; Fig. S4A). We also com-
pared LCT14 expression and methylation in 5 CRC and 4 BC
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cell lines. We could detect expression of LCT14 only in CaCo-2
and SW620 (Fig. 3B, right panel); however, all CRC lines
showed >85% methylation at this LCT (Fig. 3C, right panel;
Fig. S4A). In BC cells, we observed the predicted pattern of no
expression and high methylation in HMEC, and high expres-
sion and no methylation in T47D; however, we saw expression
of LCT14 in MCF7 cells that have levels of methylation compa-
rable to those in HMEC, and some expression in HCC1954
with about 45% methylation (Fig. S4B and C). These observa-
tions are consistent with those made at LCT13 suggesting that
at least in the context of CRC, transcription and methylation of
LCT14 are not always mutually exclusive (Fig. S5). However,
caution must be taken when interpreting these results because
we used bisulﬁte sequencing to assess the levels of methylation.
It has been shown that this method is not able to distinguish
between methylated (5mC) and hydroxymethylated (5hmC)
cytosines, an intermediate product of cytosine demethylation.39
To address this issue, we performed hydroxymethylated DNA
immunoprecipitations (hMeDIP) on the 6 CRC cell lines and
on T47D cells that are not methylated at either LCTs. When
compared with the levels detected for the hydroxymethylated
DNA control, the levels of 5hmC at the 2 LCTs are very low in
all cell lines (Fig. 4), consistent with the reported loss in 5hmC
in cultured cells.40 To better appreciate differences between the
cell lines, we plotted the results removing the positive control
and found that levels are very low, below 5% of Input, with
slightly higher levels found at LCT14 than at LCT13 (Fig. 4,
inset). Interestingly, the 3 MSS lines and T47D have higher
5hmC levels when compared with the MSI lines, though these
differences do not reach statistical signiﬁcance for LCT13. It is
important to note that T47D that has very low to undetectable
DNA methylation by bisulﬁte sequencing at LCT14 shows lev-
els of 5hmC that are comparable to those seen at SW480 which
do not express LCT14 and have high levels of DNA methyla-
tion. Similarly, SW480 has the highest levels of 5hmC at
LCT13, but do not express this LCT. These data indicate that
there is no 5hmC enrichment at the L1–50UTR of LCT13 and
LCT14 suggesting that in some cell lines these LCTs can be
active and methylated.
Effects of DNA methylation inhibition on LCT13 expression
To further investigate the relationship between methylation
and expression of LCT13 we focused on HCT116 and RKO
cells, established cell lines that have been widely used to study
DNA methylation using inhibitors.41,42 We treated these cells
with the DNA methylation inhibitor 5-azacytidine (5-aza) and
conﬁrmed that the treatment did not affect expression of the 3
reference genes used for quantiﬁcation of RT-PCR (Fig. S6A).
Expression of TFPI-2 upon 5-aza treatment, a gene known to
be induced in cancer cells upon this treatment,43 conﬁrmed its
effectiveness (Fig. S6B). Comparison of LCT13 expression and
Figure 2. Relationship between L1–50UTR methylation and LCT13 transcription start sites in cell lines. (A) Schematic diagram showing the 50UTR of the L1PA2 driving
LCT13 (chr7: 93,220,579–93,221,079) with indicated the regions analyzed by bisulﬁte sequencing (black bar; chr7: 93,220,643–93,221,121) and the positions of the 29
CpG sites (vertical black lines) within it. All coordinates are from hg19 annotations and the scale is in base pairs (bp). Indicated are all the transcription start sites (TSS;
bent arrows) identiﬁed in the cell lines by 50RACE demonstrating scattered transcription initiation (light gray) (see also Fig. S3). (B) Diagrams combining the lollipops sum-
marizing the average methylation at each of the 29 CpG site analyzed in the panels of colorectal (CRC) and breast (BC) cancer cell lines (see Fig. S2) with the stronger TSS
site identiﬁed for the particular cell line (thick bent arrows). No TSS was identiﬁed by 50RACE in RKO and SW480 cell lines, consistent with lack of detectable LCT13 tran-
scripts in these cells (Fig. 1B, right panel).
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methylation proﬁles in untreated, 5-aza or vehicle alone
(DMSO) treated cells revealed that the 5-aza treatment has no
effect on LCT13 expression (Fig. 5A) or levels of DNA methyla-
tion (Fig. 5B; Fig. S6C) in either cell lines.
The apparent lack of direct relationship between DNA
methylation and regulation of LCT13 was further supported by
the analysis of LCT13 expression in HCT116 lacking the main-
tenance (DNMT1) or de novo (DNMT3B) or both DNA meth-
yltransferases.44,45 Surprisingly, a statistically signiﬁcant
decrease in the levels of LCT13 is seen in HCT116 cells lacking
either DNMT1 or DNMT3B relatively to wild type cells while
no signiﬁcant differences are seen in HCT116 lacking both
DNMTs (Fig. 5C), consistent with the data from 5-aza treat-
ment. Taken together these data suggest that in HCT116 cells
regulation of the promoter of LCT13 relies on a more complex
regulatory mechanism including factors other than DNA
methylation.
Proﬁle of histone modiﬁcation at LCT13 and LCT14 in
cancer cells
To gain a deeper insight into the epigenetic regulation of
LCT13 and LCT14, we performed chromatin immunoprecipi-
tation (ChIP) assays using antibodies raised against the active
chromatin histone modiﬁcation H3K4me3, and the
heterochromatin associated marks H3K9me3, H3K27me3, and
H4K20me3. We tested CRC cell lines HCT116 that express
LCT13 but not LCT14, and RKO that are negative for both
LCTs (Figs 1 and 3). As a comparison, we also analyzed the BC
cell lines T47D and MCF-7, that express both LCTs but show
no or some methylation at the 2 L1–50UTR, respectively
(Figs. S2 and S4). The modiﬁcation showing a more evident dif-
ference between expressed and non-expressed LCTs in the CRC
lines is H4K20me3. LCTs that are not expressed (LCT14 in
HCT116 and LCT13 and 14 in RKO) have an enrichment in
H4K20me3 that is >25% Input (Fig. 6, top and bottom left
panels), a ﬁnding consistent with this modiﬁcation being
enriched at LINE-1 sequences.46 Surprisingly we found that
enrichment in H3K4me3 at LCT13 in HCT116 cells was very
modest, despite the fact that this LCT is expressed in these cells
(Fig. 1B); however, this ﬁnding is in agreement with the high
levels of DNA methylation at LCT13 in HCT116 cells (Fig. 1C)
and with the reported mutual exclusivity of these 2 modiﬁca-
tions.47,48 BC cells T47D that are not methylated at either loci,
show the highest levels of H3K4me3 at both L1–50UTRs (Fig. 6,
top right panel), while lower levels are seen in MCF-7 cells
(Fig. 6, bottom right panel). Levels of H4K20me3 at the LCT13
50UTR are lower than those of H3K4me3 in both T47D and
MCF-7 cells; by contrast, levels of H4K20me3 at the LCT14
50UTR in both cell lines are comparable to those of H3K4me3
Figure 3. Relationship between methylation and expression of LCT14 in CRC. (A) Schematic diagram of the LCT14 genomic locus on human chromosome 5 (coordinates:
24,487,209–27,038,689) with indicated positions of the annotated genes CDH10, LOC105374693, and CDH9 and of the intact intergenic LINE1 (L1) that drives transcription
of LCT14. At the bottom is an enlargement of the region including the LINE-1 (L1PA2; chr5:25,378,639–25,384,665) from which LCT14 originates with the regions (black
bars) tested by bisulﬁte or hydroxymethylated DNA (hMeDIP) and chromatin (ChIP) immunoprecipitations and, below these, the LCT14 transcript (chr5: 25,384,485–
25,384,958) and the region ampliﬁed for expression studies. All coordinates are from hg19 annotations; scale is in kb. (B) Expression of LCT14 measured by real-time RT-
PCR and expressed relatively to the geometric mean of 3 reference genes in matched normal (dark gray) and tumor (light gray) tissues from 4 colorectal cancer patients
(left panel) and of 5 colorectal cancer cell lines (right panel). (C) Methylation levels measured by bisulﬁte sequencing in the paired normal and tumor tissues of the 4
patients (left panel) and cell lines (right panel) described in B.
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(Fig. 6, top and bottom right panels). Interestingly, LCT13 that
is not upregulated by 5-aza in RKO cells (Fig. 4A) has low
H3K4me3 and high H4K20me3 similar to what observed at the
silenced LCT14 in HCT116 cells (Fig. 6, top and bottom left
panels). Instead, LCT14 that is expressed upon 5-aza treatment
in RKO (Fig. S7A), displays comparable H3K4me3 and
H4K20me3 levels of enrichment in these cells (Fig. 6, bottom
left panel), a pattern similar to that observed at the expressed
LCT13 in HCT116 and at the expressed LCT14 in T47D and
MCF-7 cells (Fig. 6). Although no overall changes in methyla-
tion levels are observed between treated and untreated cells
(Fig. S7B), LCT14 expression in 5-aza treated RKO cells is asso-
ciated with decrease in methylation at a speciﬁc CpG site (Fig.
S7C). This data suggest that that the relative enrichment in
H4K20me3 at LCTs is better than DNA methylation at predict-
ing whether a LINE-1 promoter is active or likely to be sensitive
to 5-aza treatment.
Discussion
Cancer is a complex genetic disease, resulting from the accu-
mulation of several genetic mutations and epigenetic changes
that allow cells to overcome the normal biologic hurdles and
defense mechanisms limiting growth and division. Decreases in
methylation at repetitive DNA is probably the most accepted
paradigm among the global changes in cancer, so much so that
loss of LINE-1 methylation is repeatedly used as a surrogate
biomarker for measuring global DNA hypomethylation.49–52
Figure 4. Analysis of 5hmC at LCT13 and LCT14 in cancer cell lines. Levels of hydroxymethylcytosine (hmeC) obtained by hMeDIP and expressed as % of Input. hmeCTRL:
hydroxymethylated control DNA; meCTRL: methylated control DNA; unCTRL: unmethylated control DNA. The inset shows an enlargement of the region of the graph with-
out the positive hmeCTRL indicating that some cell lines (Caco-2, SW480, SW620 and T47D) show minor enrichment at LCT13 and LCT14 L1ASPs, relative to the negative
controls and the negative cell lines.
Figure 5. Effects of DNA methylation inhibition in colon cancer cell lines. Expression (A) and methylation (B) of LCT13 in HCT116 cells untreated or treated with DMSO
vehicle alone or 1 mM 5-aza in DMSO. Treatment with 5-aza has no effect on LCT13 expression levels; no overall changes in the levels of DNA methylation are seen in
either cell line. (C) Expression proﬁle of LCT13 in HCT116 that are either wild type or lacking DNA methyltransferase 1 (DNMT1-KO), or 3B (DNMT3B-KO), or both DNMT1
and 3B (DKO). P values were calculated by one-way ANOVA. : P < 0.001
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Nevertheless, a signiﬁcant decrease in LINE-1 methylation has
not been seen in all cancer types. Susceptibility to LINE-1
hypomethylation appears to be cell and tissue speciﬁc and
might be dependent on cancer type or subsets of a speciﬁc can-
cer type.53–55 Moreover, emerging evidence suggest that not all
LINE-1s are regulated in the same way.56 Global LINE-1 meth-
ylation studies are unable to provide evidence for a relationship
between methylation at individual LINE-1 and their activity.
The observation that genes commonly downregulated in cancer
are more likely to contain an intragenic LINE-1 indicates that
the positioning of the LINE-1 is an important factor in its regu-
lation.57 In agreement with genome-wide studies, loss of meth-
ylation at intronic LINE-1 situated within c-MET, RAB3IP, and
CHRM3 genes was found to lead to activation of transcription
from L1-ASP.36,37,58 However, recent reports have shown that
in mouse adult, embryonic and primordial germ cells loss of
LINE-1 methylation does not always coincide with activation
of transcription.34,35,59 In addition, the repressive role of DNA
methylation at LINE-1 promoters was questioned in a study in
early development in mouse embryos that identiﬁed loss of the
active histone H3K4me3 mark as the reason for decrease in L1
expression at the 8-cell stage compared with the 2-cell stage.60
Although these observations were made in mouse, which have
LINE-1s that are different from humans, the majority of the
studies in human colorectal cancer also point to the lack of a
direct linear relationship between LINE-1 hypomethylation lev-
els and tumor stage,27,61–63 suggesting that, in man and in
mouse, DNA methylation cannot be the key regulator of
expression from all LINE-1s.
In this study, methylation levels at the L1–50UTR of 2 inter-
genic LINE-1s were investigated and compared with the levels
of their speciﬁc LCT transcripts, LCT13 and LCT14. It must be
noted that we were able to analyze region 1–436 of the L1–
50UTR of the 2 LCTs and, therefore, we did not include the L1-
ASP promoter core activity that has been proposed to map
between positions 450 and 600 of the 50UTR.13,14 A direct cor-
relation was not observed between LCT13 or LCT14 expression
and methylation in the CRC patient samples, where, except for
2 individuals, LCT13 and LCT14 methylation levels were found
to be high in both tumors and matched normal tissues regard-
less of their expression (Figs 1 and 3). The lack of a direct rela-
tionship between DNA methylation and promoter activity
within the L1–50UTRs of LCT13 and LCT14 was also observed
in the breast and colon cancer cell lines analyzed, albeit in
breast cells there was evidence of an inverse correlation
between methylation and expression levels. Differential methyl-
ation and expression levels of LINE-1 elements in different cell
lines and during different stages of development have been
documented previously.64–66 However, it is also possible that
changes in LINE-1 methylation levels can have different effects
on an individual LINE-1 promoter activity depending not only
on its unique location and surrounding DNA but also on the
cell type and whether the transcription machinery or silencing
complexes are available. We have further characterized LCT13
by 50RACE in these cell lines and we found that LCT13 tran-
scription starts within L1–50UTR in all expressing cell lines,
and DNA methylation alone does not seem to be sufﬁcient to
prevent transcription (Fig. 2). Consistent with a lack of rela-
tionship between methylation and expression of LCT13, 5-aza
treatment did not appear to affect L1-ASP methylation levels
nor LCT13 expression in HCT116 or RKO cells; however, cau-
tion must be taken when interpreting these data given that at
the dose used there was no reduction of methylation at the
LCT loci tested. Nevertheless, in agreement with the 5-aza ﬁnd-
ings, we found that HCT116 cells lacking both DNMT1 and
DNMT3B show no changes in LCT13 expression relative to
Figure 6. Histone modiﬁcations at LCT13 and LCT14 in cancer cell lines. ChIP assays performed using antibodies against active (H3K4me3) and repressive (H3K9me3,
H3K27me3, H4K20me3) histone marks in LCT13 positive and LCT14 negative HCT116 cells (top left panel), in LCT13 and LCT14 negative RKO cells (bottom left panel), and
in LCT13 and LCT14 positive T47D (top right panel) and MCF-7 (bottom right panel) cells. GAPDH is a promoter Taqman assay used as a positive control for H3K4me3 and
APRT-30UTR has been previously shown to be enriched at repressive mark H4K20me3.
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wild type cells; however, knockout of either DNMTs led to a
signiﬁcant decrease in LCT13 expression (Fig. 5).
Histone modiﬁcation proﬁling at the LCT13 and LCT14 L1–
50UTRs (Fig. 6) suggest H4K20me3 as a better indicator than
DNA methylation to determine LCT expression or sensitivity
to 5-aza. This modiﬁcation has been previously shown to be
enriched at LINE-1s in CRC,67 and a recent study has reported
variation in the levels of H4K20me3 at different LINE-1 sub-
types.68 We found that in HCT116 and RKO cells we could not
induce expression of the LCTs that had a relative enrichment
in H4K20me3 at levels above 40% of Input (LCT14 and
LCT13, respectively) with 5-aza under the conditions used
(Fig. 5 and Fig. S7). Future experiments will be necessary to
demonstrate the correlation between H4K20me3 and LCT acti-
vation, for example, by testing if loss of H4K20me3 (SUV4–20
knockdown) in cells in which LCTs are repressed is sufﬁcient
to upregulate expression. Moreover, extending the repertoire of
unique LINE-1s analyzed will be necessary to conﬁrm the gen-
erality of this ﬁnding. This knowledge will be very important in
the context of clinical applications of therapeutic agents such as
5-aza. For example, a therapy likely to promote activation of
the LINE-1 promoter driving LCT13 or that intragenic to
cMET could increase the risk of developing cancer by promot-
ing silencing of the metastasis suppressor gene TFPI-2 or
expression of the oncogenic isoform L1-MET.37,38
In conclusion, our data indicate that DNA methylation may
not always play a key role in silencing the L1–50UTRs of inter-
genic LINE-1s similar to those driving LCT13 and LCT14. It is
more likely that the regulation of these promoters is achieved
by a dynamic network and interplay between several factors
that are compromised in some but not all cases of breast and
colorectal tumors. Further investigations are needed to estab-
lish the other regulatory factors involved in LINE-1 promoter
control and the exact role of DNA methylation in this process.
Materials and methods
Patient details and ethics
Ethical approval for this study was granted by the Derbyshire
Research Ethics Committee for the collection of normal and
cancer colorectal tissues from patients who underwent surgical
resection at the Royal Derby Hospital (Derby, UK) after
informed written consent was obtained. All tumors collected
were large specimens of size ranging from 2.25 cm3 to 42 cm3;
the sections used had  75% tumor cells
Cell lines cultures and 5-azacytidine treatment
Cancer cell lines were obtained from ECACC (HCA-7,
HCT116, CaCo2, SW620, SW480, MCF-7) or ATCC (RKO,
HCC1954) and cultured according to the guidelines from the
providers. HMEC (Invitrogen) were kindly provided by Dr.
Allegrucci as frozen cell pellets ready for nucleic acid extrac-
tion. DNA samples from the cell lines were sent to Bio-Synthe-
sis, Inc. for STR proﬁling to conﬁrm cell line identity.
HCT116 and RKO Cells were treated for 72 h with 1 mM 5-
azacytidine (Sigma, Cat. no. A2385) replacing the media every
24 h with fresh media containing 1 mM 5-aza. The HCT116
DNMT knockout cells were kindly donated by B. Vogelstein
for the work published in69 and their identity conﬁrmed at that
time via expression analysis and DNA methylation proﬁles.
Cell pellets used for the analyses described in the present man-
uscript were prepared by Dr. Ottaviano from the same cultures,
subsequently checked by expression analysis and DNA methyl-
ation proﬁles (manuscript in preparation).
Nucleic acids extractions and RT-PCR
DNA and total RNA was extracted from tissues and cell lines
using Allprep RNA/DNA mini kit (QIAGEN, Cat. no. 80204)
according to the manufacturer’s instructions, including the on
column DNaseI treatment (QIAGEN, Cat. no. 79254) for RNA
extraction. RNA integrity was evaluated by agarose gel electro-
phoresis. Reverse transcription was performed on 60 ng of
RNA with random primers using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Cat. no. 4374966) in a
ﬁnal volume of 20 ml and following manufacturer’s instruc-
tions. An aliquot (2 ml) of the reverse transcription reaction
was used for real-time PCR and each sample was analyzed in
triplicate. Real time PCR was performed using custom designed
Taqman assays for the LCTs and commercially available Taq-
man assays for the house keeping genes (Applied Biosystems).
The thermocycling parameters were as follows: 10 min at 95C,
followed by 45 cycles of 15 s at 95C, and 1 min at 60C. Details
of all Taqman assays used can be found in Table S1. Processing
and analysis of real-time PCR data was performed on GenEx
software (bioMCC, Germany). Levels of LCT RNA expression
were expressed relatively to the geometric mean of 3 reference
genes (HPRT, PGK, and GAPDH; see Supplementary Methods
and Fig. S1).
Bisulﬁte
Bisulﬁte conversion of DNA was performed using EZ DNA
Methylation-Gold Kit (Zymo research, Cat. no. D5005) accord-
ing to the manufacturer’s protocol. Primary and secondary
PCRs were performed using ZymoTaq (Zymo Research, Cat.
no. E2001) in a ﬁnal volume of 25 ml, under the following con-
ditions: 10 min incubation at 95C before 40 cycles of 30 sec at
95C, 1 min at 48C (49C for TFPI2 primary primer pair) and
1 min at 72C. Finally, the samples were incubated at 72C for
10 min. Bisulﬁte treated DNA (40 ng) was used in the primary
PCR reaction; 1 ml of the primary PCR was used as template
for the secondary PCR. All primers were used at a ﬁnal concen-
tration of 0.6 mM (see Table S2 for details of primers). PCR
products were puriﬁed from the gel using QIAquick Gel
Extraction kit (QIAGEN, Cat. no. 28704) and cloned using
pGEM-T Easy Vector System I (Promega, Cat. no. A1360).
Transformation was performed using XL10 Gold ultra-compe-
tent cells (Agilent Technologies, Cat. no. 200315) followed by
selection on ampicillin (Sigma-Aldrich, Cat. no. A9518) con-
taining plates following standard protocols. Plasmid puriﬁca-
tion was performed using QIAprep Spin miniprep kit
(QIAGEN, Cat. no. 27106) or PureYieldTM Plasmid Miniprep
System (Promega, Cat. no. A1223). Plasmid DNA was sent to
Source Biosciences for Sanger sequencing. Sequencing data was
analyzed using MacVectorTM 8.0 and bisulﬁte analysis was
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performed using the BIQ analyzer excluding clones with esti-
mated conversion rates below 90% and clones 100% identical
to another clone unless the overall methylation state was close
to 0% or 100%.70
50RACE
50RACE was performed as described previously,15 except that
the LCT13 reverse transcription primer (NV009:
50TTTGTCCTTTTCTGTCAGGTCCTC30) and the gene spe-
ciﬁc primers for primary (NV010: 50GCATCTTTTTGC
CTGTTGTGGA30) and secondary (NV011: 50ATCTTT
TTGCCTGTTGTGGAGG30) PCR ampliﬁcation were designed
within exon 2 (Fig. 1A, bottom diagram). APRT was used as a
positive control using the previously published primers.15 PCR
products were gel puriﬁed, cloned, and sequenced as described
above.
hMeDIP
Immunoprecipitation of hydroxymethylated DNA was per-
formed with a mouse monoclonal antibody against 5-hydroxy-
methylcytosine (5hmC) using the hMeDIP kit (Diagenode, Cat.
no. C02010031) following the manufacturer’s instructions.
DNA samples were sheared at 4C using a Diagenode Biorup-
tor. DNA (1 mg) was used for each IP; recovered DNA was ana-
lyzed by real-time PCR (Table S3). Hydroxymethylated,
methylated, and unmethylated DNA controls and primers for
their ampliﬁcation were provided with the kit.
Chromatin IPs
Chromatin Immunoprecipitation (ChIP) assays were per-
formed using EZ-Magna ChIPTM A kit (Millipore, Cat. no. 17–
408) according to the manufacturer’s instructions. Antibodies
raised in rabbit against H3K4Me3, H3K9me3, H3K27me3, and
H4K20me3 were purchased from Diagenode (Cat. no. pAb-
003–050, pAb-056–050, pAb-069–050 and pAb-057–050,
respectively). Rabbit IgG was provided with the ChIP kit. Cells
were crosslinked in their culture vessel with the appropriate
media containing 1% formaldehyde (Sigma, Cat. no. F8775) for
10 min at room temperature. Cells were sonicated at 4C using
a Diagenode Bioruptor. Cells (106) were used for each IP and
the recovered material was analyzed by real-time PCR using
custom designed Taqman assays for LCT13, LCT14, and APRT
(Table S3). GAPDH primers were provided in the kit.
Financial disclosure
Research was supported by the Derby Teaching Hospitals NHS
Foundation Trust Colorectal Cancer Charitable Fund; and by
Genetic Society summer scholarships to LMM and CP. NV-I
was supported by a University Research Scholarship Doctoral
Training Award from the University of Nottingham. Research
in RRM laboratory is supported by the MRC. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Disclosure of potential conﬂicts of interest
No potential conﬂicts of interest were disclosed.
Acknowledgments
We are grateful to Dr. Cinzia Allegrucci for donating human mammary
epithelial cell pellets (HMEC) and Dr. Raffaele Ottaviano for providing the
HCT116 single and double knockout cell pellets.
ORCID
Cristina Tufarelli http://orcid.org/0000-0002-1053-4618
References
1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J,
Devon K, Dewar K, Doyle M, FitzHugh W, et al. Initial sequencing
and analysis of the human genome. Nature 2001; 409:860-921;
PMID:11237011; https://doi.org/10.1038/35057062
2. Mills RE, Bennett EA, Iskow RC, Devine SE. Which transposable ele-
ments are active in the human genome? Trends Genet 2007; 23:183-
91; PMID:17331616; https://doi.org/10.1016/j.tig.2007.02.006
3. Beck CR, Collier P, Macfarlane C, Malig M, Kidd JM, Eichler EE,
Badge RM, Moran JV. LINE-1 retrotransposition activity in human
genomes. Cell 2010; 141:1159-70; PMID:20602998; https://doi.org/
10.1016/j.cell.2010.05.021
4. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV,
Kazazian HH, Jr. Hot L1s account for the bulk of retrotransposition in
the human population. Proc Natl Acad Sci U S A 2003; 100:5280-5;
PMID:12682288; https://doi.org/10.1073/pnas.0831042100
5. Khan H, Smit A, Boissinot S. Molecular evolution and tempo of
ampliﬁcation of human LINE-1 retrotransposons since the origin of
primates. Genome Res 2006; 16:78-87; PMID:16344559; https://doi.
org/10.1101/gr.4001406
6. Gifford WD, Pfaff SL, Macfarlan TS. Transposable elements as genetic
regulatory substrates in early development. Trends Cell Biol 2013;
23:218-26; PMID:23411159; https://doi.org/10.1016/j.tcb.2013.01.001
7. Goodier JL, Kazazian HH, Jr. Retrotransposons revisited: the restraint
and rehabilitation of parasites. Cell 2008; 135:23-35; PMID:18854152;
https://doi.org/10.1016/j.cell.2008.09.022
8. Tufarelli C, Badge RM. In Cristofari G. (ed.), Human Retrotranspo-
sons in Health and Disease. Springer, 2016:pp. 259-73; https://doi.org/
10.1007/978-3-319-48344-3_11
9. Faulkner GJ, Kimura Y, Daub CO, Wani S, Plessy C, Irvine KM,
Schroder K, Cloonan N, Steptoe AL, Lassmann T, et al. The regulated
retrotransposon transcriptome of mammalian cells. Nat Genet, 2009;
41:563-71; PMID:19377475; https://doi.org/10.1038/ng.368
10. Speek M. Antisense promoter of human L1 retrotransposon drives
transcription of adjacent cellular genes. Mol Cell Biol 2001; 21:1973-
85; PMID:11238933; https://doi.org/10.1128/MCB.21.6.1973-
1985.2001
11. Swergold GD. Identiﬁcation, characterization, and cell speciﬁcity of a
human LINE-1 promoter. Mol Cell Biol 1990; 10:6718-29;
PMID:1701022; https://doi.org/10.1128/MCB.10.12.6718
12. Yang N, Kazazian HH, Jr. L1 retrotransposition is suppressed by
endogenously encoded small interfering RNAs in human cultured
cells. Nat Struct Mol Biol 2006; 13:763-71; PMID:16936727; https://
doi.org/10.1038/nsmb1141
13. Macia A, Munoz-Lopez M, Cortes JL, Hastings RK, Morell S, Lucena-
Aguilar G, Marchal JA, Badge RM, Garcia-Perez JL. Epigenetic control
of retrotransposon expression in human embryonic stem cells. Mol
Cell Biol 2011; 31:300-16; PMID:21041477; https://doi.org/10.1128/
MCB.00561-10
14. Denli AM, Narvaiza I, Kerman BE, Pena M, Benner C, Marchetto MC,
Diedrich JK, Aslanian A, Ma J, Moresco JJ, et al. Primate-speciﬁc
ORF0 contributes to retrotransposon-mediated diversity. Cell 2015;
EPIGENETICS 473
163:583-593; PMID:26496605; https://doi.org/10.1016/j.
cell.2015.09.025
15. Cruickshanks HA, Tufarelli C. Isolation of cancer-speciﬁc chimeric
transcripts induced by hypomethylation of the LINE-1 antisense pro-
moter. Genomics 2009; 94:397-406; PMID:19720139; https://doi.org/
10.1016/j.ygeno.2009.08.013
16. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-
92; PMID:17320506; https://doi.org/10.1016/j.cell.2007.01.029
17. Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the
ecology of intragenomic parasites. Trends Genet 1997; 13:335-40;
PMID:9260521; https://doi.org/10.1016/S0168-9525(97)01181-5
18. Harony H, Bernes S, Siman-Tov R, Ankri S. DNA methylation and
targeting of LINE retrotransposons in Entamoeba histolytica and
Entamoeba invadens. Mol Biochem Parasitol 2006; 147:55-63;
PMID:16530279; https://doi.org/10.1016/j.molbiopara.2006.02.005
19. Hata K, Sakaki Y. Identiﬁcation of critical CpG sites for repression of
L1 transcription by DNA methylation. Gene 1997; 189:227-34;
PMID:9168132; https://doi.org/10.1016/S0378-1119(96)00856-6
20. Steinhoff C, Schulz WA. Transcriptional regulation of the human
LINE-1 retrotransposon L1.2B. Mol Genet Genomics 2003;
270:394-402; PMID:14530963; https://doi.org/10.1007/s00438-003-
0931-2
21. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of
some human cancers from their normal counterparts. Nature 1983;
301:89-92; PMID:6185846; https://doi.org/10.1038/301089a0
22. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal insta-
bility and tumors promoted by DNA hypomethylation. Science
2003; 300:455; PMID:12702868; https://doi.org/10.1126/
science.1083557
23. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray
JW, Leonhardt H, Jaenisch R. Induction of tumors in mice by genomic
hypomethylation. Science 2003; 300:489-92; PMID:12702876; https://
doi.org/10.1126/science.1083558
24. Symer DE, Connelly C, Szak ST, Caputo EM, Cost GJ, Parmigiani G,
Boeke JD. Human l1 retrotransposition is associated with genetic
instability in vivo. Cell 2002; 110:327-38; PMID:12176320; https://doi.
org/10.1016/S0092-8674(02)00839-5
25. Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA. DNA methylation
and expression of LINE-1 and HERV-K provirus sequences in urothe-
lial and renal cell carcinomas. Br J Cancer 1999; 80:1312-21;
PMID:10424731; https://doi.org/10.1038/sj.bjc.6690524
26. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High
frequency of alterations in DNA methylation in adenocarcinoma of
the prostate. Prostate 1999; 39:166-74; PMID:10334105; https://doi.
org/10.1002/(SICI)1097-0045(19990515)39:3<166::AID-PROS4>3.0.
CO;2-J
27. Sunami E, de Maat M, Vu A, Turner RR, Hoon DS. LINE-1
hypomethylation during primary colon cancer progression. PLoS
One 2011; 6:e18884; PMID:21533144; https://doi.org/10.1371/
journal.pone.0018884
28. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ, 3rd,
Lohr JG, Harris CC, Ding L, Wilson RK, et al. Landscape of somatic
retrotransposition in human cancers. Science 2012; 337:967-71;
PMID:22745252; https://doi.org/10.1126/science.1222077
29. Kazazian HH, Jr. Mobile elements: drivers of genome evolution. Sci-
ence 2004; 303:1626-32; PMID:15016989; https://doi.org/10.1126/
science.1089670
30. Deininger PL, Moran JV, Batzer MA, Kazazian HH, Jr. Mobile ele-
ments and mammalian genome evolution. Curr Opin Genet Dev
2003; 13:651-658; PMID:14638329; https://doi.org/10.1016/j.
gde.2003.10.013
31. Lisanti S, Omar WA, Tomaszewski B, De Prins S, Jacobs G, Koppen
G, Mathers JC, Langie SA. Comparison of methods for quantiﬁcation
of global DNA methylation in human cells and tissues. PLoS One
2013; 8:e79044; PMID:24260150; https://doi.org/10.1371/journal.
pone.0079044
32. Smith ZD, Chan MM, Mikkelsen TS, Gu H, Gnirke A, Regev A,
Meissner A. A unique regulatory phase of DNA methylation in the
early mammalian embryo. Nature 2012; 484:339-44; PMID:22456710;
https://doi.org/10.1038/nature10960
33. Phokaew C, Kowudtitham S, Subbalekha K, Shuangshoti S, Mutiran-
gura A. LINE-1 methylation patterns of different loci in normal and
cancerous cells. Nucleic Acids Res 2008; 36:5704-12; PMID:18776216;
https://doi.org/10.1093/nar/gkn571
34. Hackett JA, Reddington JP, Nestor CE, Dunican DS, Branco MR,
Reichmann J, Reik W, Surani MA, Adams IR, Meehan RR. Promoter
DNA methylation couples genome-defence mechanisms to epigenetic
reprogramming in the mouse germline. Development 2012; 139:3623-
32; PMID:22949617; https://doi.org/10.1242/dev.081661
35. Dunican DS, Cruickshanks HA, Suzuki M, Semple CA, Davey T,
Arceci RJ, Greally J, Adams IR, Meehan RR. Lsh regulates LTR retro-
transposon repression independently of Dnmt3b function. Genome
Biol 2013; 14:R146; PMID:24367978; https://doi.org/10.1186/gb-2013-
14-12-r146
36. Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, Goel
A. Hypomethylation of long interspersed nuclear element-1 (LINE-1)
leads to activation of proto-oncogenes in human colorectal cancer
metastasis. Gut 2013; 63:635-46; PMID:23704319; https://doi.org/
10.1136/gutjnl-2012-304219
37. Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD,
Yang AS, Jones PA, Liang G. Hypomethylation of a LINE-1 promoter
activates an alternate transcript of the MET oncogene in bladders
with cancer. PLoS Genet 2010; 6:e1000917; PMID:20421991; https://
doi.org/10.1371/journal.pgen.1000917
38. Cruickshanks HA, Vafadar-Isfahani N, Dunican DS, Lee A, Sproul D,
Lund JN, Meehan RR, Tufarelli C. Expression of a large LINE-1-
driven antisense RNA is linked to epigenetic silencing of the metasta-
sis suppressor gene TFPI-2 in cancer. Nucleic Acids Res 2013;
41:6857-69; PMID:23703216; https://doi.org/10.1093/nar/gkt438
39. Nestor C, Ruzov A, Meehan R, Dunican D. Enzymatic approaches and
bisulﬁte sequencing cannot distinguish between 5-methylcytosine and
5-hydroxymethylcytosine in DNA. Biotechniques 2010; 48:317-9;
PMID:20569209; https://doi.org/10.2144/000113403
40. Nestor CE, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Duni-
can D, Katz E, Dixon JM, Harrison DJ, Meehan RR. Tissue type is a
major modiﬁer of the 5-hydroxymethylcytosine content of human
genes. Genome Res 2012; 22:467-77; PMID:22106369; https://doi.org/
10.1101/gr.126417.111
41. Kim JG, Bae JH, Kim JA, Heo K, Yang K, Yi JM. Combination effect of
epigenetic regulation and ionizing radiation in colorectal cancer cells.
PLoS One 2014; 9:e105405; PMID:25136811; https://doi.org/10.1371/
journal.pone.0105405
42. Weber B, Kimhi S, Howard G, Eden A, Lyko F. Demethylation of a
LINE-1 antisense promoter in the cMet locus impairs Met signalling
through induction of illegitimate transcription. Oncogene 2010;
29:5775-84; PMID:20562909; https://doi.org/10.1038/onc.2010.227
43. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA,
Eshleman JR, Goggins M. Epigenetic inactivation of TFPI-2 as a com-
mon mechanism associated with growth and invasion of pancreatic
ductal adenocarcinoma. Oncogene 2005; 24:850-8; PMID:15592528;
https://doi.org/10.1038/sj.onc.1208050
44. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW,
Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained
in human cancer cells lacking DNMT1. Nature 2000; 404:1003-7;
PMID:10801130; https://doi.org/10.1038/35010000
45. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui
H, Feinberg AP, Lengauer C, Kinzler KW, et al. DNMT1 and
DNMT3b cooperate to silence genes in human cancer cells. Nature
2002; 416:552-6; PMID:11932749; https://doi.org/10.1038/416552a
46. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Rein-
berg D, Jenuwein T. A silencing pathway to induce H3-K9 and H4-
K20 trimethylation at constitutive heterochromatin. Genes Dev 2004;
18:1251-62; PMID:15145825; https://doi.org/10.1101/gad.300704
47. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-
Bromage H, Tempst P, Lin SP, Allis CD, et al. DNMT3L connects
unmethylated lysine 4 of histone H3 to de novo methylation of
DNA. Nature 2007; 448:714-7; PMID:17687327; https://doi.org/
10.1038/nature05987
48. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M,
Schubeler D. Distribution, silencing potential and evolutionary
474 N. VAFADAR-ISFAHANI ET AL.
impact of promoter DNA methylation in the human genome. Nat
Genet 2007; 39:457-66; PMID:17334365; https://doi.org/10.1038/
ng1990
49. Link A, Balaguer F, Shen Y, Lozano JJ, Leung HC, Boland CR, Goel A.
Curcumin modulates DNA methylation in colorectal cancer cells.
PLoS One 2013; 8:e57709; PMID:23460897; https://doi.org/10.1371/
journal.pone.0057709
50. Schulz WA. L1 retrotransposons in human cancers. J Biomed Biotech-
nol 2006; 2006:83672; PMID:16877821; https://doi.org/10.1155/JBB/
2006/83672
51. Tapp HS, Commane DM, Bradburn DM, Arasaradnam R, Math-
ers JC, Johnson IT, Belshaw NJ. Nutritional factors and gender
inﬂuence age-related DNA methylation in the human rectal
mucosa. Aging Cell 2013; 12:148-55; PMID:23157586; https://doi.
org/10.1111/acel.12030
52. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human
diseases. Biochim Et Biophys Acta 2007; 1775:138-62;
PMID:17045745; https://doi.org/10.1016/j.bbcan.2006.08.007
53. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N,
Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V,
Mutirangura A. Distinctive pattern of LINE-1 methylation level in nor-
mal tissues and the association with carcinogenesis. Oncogene 2004;
23:8841-46; PMID:15480421; https://doi.org/10.1038/sj.onc.1208137
54. Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R,
Ackermann R, Schulz WA. Coordinate hypermethylation at speciﬁc
genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J
Cancer 2004; 91:985-94; PMID:15292941; https://doi.org/10.1038/sj.
bjc.6602030
55. Thayer RE, Singer MF, Fanning TG. Undermethylation of speciﬁc
LINE-1 sequences in human cells producing a LINE-1-encoded pro-
tein. Gene 1993; 133:273-277; PMID:7693554; https://doi.org/
10.1016/0378-1119(93)90651-I
56. Philippe C, Vargas-Landin DB, Doucet AJ, van Essen D, Vera-Otarola
J, Kuciak M, Corbin A, Nigumann P, Cristofari G. Activation of indi-
vidual L1 retrotransposon instances is restricted to cell-type depen-
dent permissive loci. eLife 2016; 5:e13926; PMID:27016617; https://
doi.org/10.7554/eLife.13926
57. Aporntewan C, Phokaew C, Piriyapongsa J, Ngamphiw C, Ittiwut C,
Tongsima S, Mutirangura A. Hypomethylation of intragenic LINE-1
represses transcription in cancer cells through AGO2. PLoS One
2011; 6:e17934; PMID:21423624; https://doi.org/10.1371/journal.
pone.0017934
58. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez
J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, et al. Pro-
moter hypomethylation of the LINE-1 retrotransposable elements
activates sense/antisense transcription and marks the progression of
chronic myeloid leukemia. Oncogene 2005; 24:7213-23;
PMID:16170379; https://doi.org/10.1038/sj.onc.1208866
59. Seisenberger S, Andrews S, Krueger F, Arand J, Walter J, Santos F,
Popp C, Thienpont B, Dean W, Reik W. The dynamics of genome-
wide DNA methylation reprogramming in mouse primordial germ
cells. Mol Cell 2012; 48:849-62; PMID:23219530; https://doi.org/
10.1016/j.molcel.2012.11.001
60. Fadloun A, Le Gras S, Jost B, Ziegler-Birling C, Takahashi H, Gorab E,
Carninci P, Torres-Padilla ME. Chromatin signatures and retrotrans-
poson proﬁling in mouse embryos reveal regulation of LINE-1 by
RNA. Nat Struct Mol Biol 2013; 20:332-8; PMID:23353788; https://
doi.org/10.1038/nsmb.2495
61. Matsunoki A, Kawakami K, Kotake M, Kaneko M, Kitamura H, Ooi
A, Watanabe G, Minamoto T. LINE-1 methylation shows little intra-
patient heterogeneity in primary and synchronous metastatic colorec-
tal cancer. BMC Cancer 2012; 12:574; PMID:23216958; https://doi.
org/10.1186/1471-2407-12-574
62. Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T,
Iwatsuki M, Iwagami S, Sakamoto Y, Miyamoto Y, et al. Methylation
levels of LINE-1 in primary lesion and matched metastatic lesions of
colorectal cancer. Br J Cancer 2013; 109:408-15; PMID:23764749;
https://doi.org/10.1038/bjc.2013.289
63. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer
ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1
hypomethylation and prognosis in colon cancer. J Natl Cancer Inst
2008; 100:1734-8; PMID:19033568; https://doi.org/10.1093/jnci/
djn359
64. Belancio VP, Hedges DJ, Deininger P. LINE-1 RNA splicing and inﬂu-
ences on mammalian gene expression. Nucleic Acids Res 2006;
34:1512-21; PMID:16554555; https://doi.org/10.1093/nar/gkl027
65. Ergun S, Buschmann C, Heukeshoven J, Dammann K, Schnieders
F, Lauke H, Chalajour F, Kilic N, Stratling WH, Schumann GG.
Cell type-speciﬁc expression of LINE-1 open reading frames 1 and
2 in fetal and adult human tissues. J Biol Chem 2004; 279:27753-
63; PMID:15056671; https://doi.org/10.1074/jbc.M312985200
66. Kines KJ, Belancio VP. Expressing genes do not forget their LINEs:
transposable elements and gene expression. Frontiers Biosci 2012;
17:1329-44; PMID:22201807; https://doi.org/10.2741/3990
67. Gezer U, Ustek D, Yoruker EE, Cakiris A, Abaci N, Leszinski G, Dalay
N, Holdenrieder S. Characterization of H3K9me3- and H4K20me3-
associated circulating nucleosomal DNA by high-throughput
sequencing in colorectal cancer. Tumour Biol 2013; 34:329-36;
PMID:23086575; https://doi.org/10.1007/s13277-012-0554-5
68. Nelson DM, Jaber-Hijazi F, Cole JJ, Robertson NA, Pawlikowski JS,
Norris KT, Criscione SW, Pchelintsev NA, Piscitello D, Stong N, et al.
Mapping H4K20me3 onto the chromatin landscape of senescent cells
indicates a function in control of cell senescence and tumor suppres-
sion through preservation of genetic and epigenetic stability. Genome
Biol 2016; 17:158; PMID:27457071; https://doi.org/10.1186/s13059-
016-1017-x
69. Sproul D, Nestor C, Culley J, Dickson JH, Dixon JM, Harrison
DJ, Meehan RR, Sims AH, Ramsahoye B.H. Transcriptionally
repressed genes become aberrantly methylated and distinguish
tumors of different lineages in breast cancer. Proc Natl Acad Sci
U S A 2011; 108:4364-9; PMID:21368160; https://doi.org/10.1073/
pnas.1013224108
70. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ
Analyzer: visualization and quality control for DNA methylation data
from bisulﬁte sequencing. Bioinformatics 2005; 21:4067-8;
PMID:16141249; https://doi.org/10.1093/bioinformatics/bti652
EPIGENETICS 475
